View all IQVIA events
An increasing number of SME and Emerging Biotechs are choosing to retain commercialization rights for their key assets in the mature global as well as in the emerging markets of Asia Pacific (APAC). We would like to share learnings and best practices from our experience helping to successfully commercialize innovative drug assets in the region. The session will touch upon the overall opportunity the Asia Pacific represents for local biotech companies, challenges as well as key considerations.